Merger Gamesmanship: Genentech Had Countered First Roche Bid With 26% Higher Asking Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche SEC filing outlines several “key areas of disagreement,” including assumptions on annual product price increases and pipeline productivity.